Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016235 · ClinicalTrials.gov registry record · Phase 1
Role Of Phosphorus And FGF 23 In Patients With Dent Disease
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02016235: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02016235 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02016235, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.
Interventions
- OTHER Observation
- DRUG Phosphorus Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02016235
The ClinicalTrials.gov registry entry for NCT02016235 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Observation is the first listed.
NCT02016235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02016235 about?
NCT02016235 is a clinical study titled "Role Of Phosphorus And FGF 23 In Patients With Dent Disease". Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.
What is the current status of trial NCT02016235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-09. Estimated completion is 2019-01.
What interventions are being tested in trial NCT02016235?
The interventions under investigation include: Observation (OTHER), Phosphorus Supplement (DRUG).
Who is sponsoring clinical trial NCT02016235?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.